Quantitative Computed Tomography for Mortality Risk Stratification in ARDS

NCT ID: NCT06113276

Last Updated: 2024-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

210 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-06

Study Completion Date

2025-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute respiratory distress syndrome remains a deadly disease with hospital mortality remaining between 40 to 50%. ARDS mortality risk factors have been identified from patient history, common clinical and biological variables in the lung SAFE study. Part of ARDS mortality is attributable to ventilator-induced lung injury (VILI), in relation with inappropriate settings on the ventilator. Tidal hyperinflation and recruitment/derecruitment during lung inflation are 2 identified mechanisms leading to VILI, that may be identified on computed tomography while poorly identified with variables collected at the bedside.

The aim of this study is to identify whether tidal hyperinflation identified on computed tomography is a risk factor for ARDS mortality, independently from know bio-clinical risk factors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Respiratory Distress Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

tidal hyperinflation

As the study aim to identify whether tidal hyperinflation is an independent predictor for ARDS mortality, and as this variable will be entered as a quantitative predictor in the multivariate model, the study encompass a single group of patient (i.e. all included patients)

Low dose computed tomography to evaluate biomechanical parameters in the lung

Intervention Type RADIATION

In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low dose computed tomography to evaluate biomechanical parameters in the lung

In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient aged 15 or older with ARDS according to the Berlin definition
* invasive mechanical ventilation with PaO2/FiO2 ≤ 300 mm Hg
* with computed tomography acquired at both end-expiration and end-inspiration, or at both PEEP 5 and 15 cm H2O at end-expiration
* PEEP setting according to a PEEP/FiO2 table, with secondary adjustment according to hemodynamic tolerance
* Tidal volume 6 ml/kg of predicted body weight or less

Exclusion Criteria

* Use of contrast agent during computed tomography acquisition
* ARDS criteria onset since more than 72 hours or ECMO onset since more than 72 hours
* Proven COPD
* Pneumothorax or bronchopleural fistula
* Patient with spontaneous breathing preventing realization of end-expiratory and end-inspiratory pauses
* Previous inclusion in current study
* Patient under a legal protective measure
Minimum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Médecine Intensive Réanimation Hôpital Michallon - CHU Grenoble Alpes

La Tronche, , France

Site Status RECRUITING

Hospices Civils de Lyon - Hôpital de la Croix Rousse - Service de Médecine Intensive Réanimation

Lyon, , France

Site Status RECRUITING

Service de Réanimation Polyvalente Centre Hospitalier Lyon Sud Hospices Civils de Lyon

Pierre-Bénite, , France

Site Status RECRUITING

Centre Hospitalier Universitaire de Rennes

Rennes, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nicolas TERZI, Pr

Role: primary

04-76-76-87-79 ext. +33

Jean-Christophe RICHARD

Role: primary

+33 426109272

William Danjou

Role: backup

+33 472071762

Florent WALLET, MD

Role: primary

04 78 86 21 62 ext. +33

Jean Marc TADIE, MD

Role: primary

02 99 28 43 21

References

Explore related publications, articles, or registry entries linked to this study.

Shekarnabi M, Guillien A, Terzi N, Sigaud F, Bitker L, Roux E, Ahaouari T, Serrano EED, Boussel L, Ferretti G, Yonis H, Mezidi M, Noirot I, Chauvelot L, Dhelft F, Gaillet M, Siroux V, Orkisz M, Richard JC, Bayat S. Prognostic value of functional CT imaging in COVID-ARDS: a two-centre prospective observational study. Respir Res. 2025 May 9;26(1):177. doi: 10.1186/s12931-025-03232-7.

Reference Type DERIVED
PMID: 40346553 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

194_v3

Identifier Type: REGISTRY

Identifier Source: secondary_id

69HCL21_0664

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Eit in ArdS for Tcav Setting (EAST Study)
NCT06408272 NOT_YET_RECRUITING